Project Grant R01HL174709
Award Date 8/18/25
Completion Date 5/31/30
Dollars Obligated $739K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $811,885 in funding to the J. David Gladstone Institutes in San Francisco, California. The award supports research to investigate the epigenomic mechanisms governing cardiac fibrosis and heart failure pathogenesis. Key goals include understanding the role of the MEOX1 transcriptional regulator in fibroblast activation and fibrosis, with...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $561,392 to the University of Alabama at Birmingham (UAB) to investigate the role of RNA methylation in regulating the progression of cardiac fibrosis, a key contributor to heart failure. The central hypothesis is that activation of the METTL3 enzyme increases the stability of the RAPGEF5 mRNA, promoting the nuclear translocation of beta-catenin and the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...
- This federal Project Grant award of $694,252.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the mechanisms by which a small non-coding RNA called YREX3 enhances the ability of macrophages to clear dead cells and provide cardioprotection after a myocardial infarction. The 5-year project, awarded to Cedars-Sinai Medical Center, aims to 1) confirm the signaling events by which YREX3 enhances macrophage...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research to investigate the role of the IRE1 protein in regulating cardiac fibrosis. The $745,663 award, made on September 1, 2025, supports a project at the University of Utah that aims to determine how the unfolded protein response pathway mediated by IRE1 contributes to the activation of cardiac fibroblasts and the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research, aims to ameliorate cardiac fibrosis using diverse human cardiac organoid models. The $159,512 award will support research to discover and validate compounds that can combat the activation of cardiac fibroblasts, a key driver of cardiac fibrosis in dilated cardiomyopathy (DCM). The project will utilize 3D induced pluripotent stem cell-derived cardiac...
- This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $655,636 in funding to the Texas Heart Institute (THI) to investigate the role of cardiac fibroblasts in the development of heart failure in patients with single ventricle congenital heart disease. The objectives are to gain insights into the intrinsic molecular mechanisms that promote cellular senescence, metabolic remodeling, and...